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INTRODUCTION
A nonsteroidal benzothiophene derivative, raloxifene, has
a tissue-selective estrogen agonist/antagonist profile. Ralox-
ifene is a classical antiestrogen in the breast and uterus (1,
2)whereas it has a bone-preserving effect and a cholesterol
lowering effect in nonreproductive tissues as an estrogen
agonist (3, 4). Recently it was found that raloxifene sends its
bone-preserving signals to the genes by a route, different
from the one traced for estrogen in reproductive tissues (5).
Activation of the gene encoding transforming growth factor -
3 (TGF- 3), an important cytokine in regulating osteo-
clast differentiation (5), demonstrated a distinct pathway
from that of an estrogen response element (ERE) containing
gene. 
The novel DNA response element, raloxifene response
element (RRE), was identified in the 5′ untranslated region
of TGF- 3 gene (6). RRE-mediated pathway might be one
of the possible explanations for the wide spectrum of estro-
gen effects, especially in nonreproductive tissues including
the bone. Moreover, it might have an answer for the tissue
specificity of raloxifene that acts as an antagonist in repro-
ductive system, while acts as an agonist in non-reproductive
system.
We, therefore, hypothesized that RRE of the TGF- 3 gene
could be important in bone preservation and any mutants
on the RRE sequence could affect the development of low
bone mass. We investigated whether a polymorphic site or
mutation exists on the RRE sequence of the TGF- 3 gene
in postmenopausal Korean women. 
MATERIALS AND METHODS
Two hundred healthy postmenopausal women of Korean
ethnicity were investigated. Women with early menopause
(before 40 yr of age) and those who had had an ovariectomy
were excluded. None had a history of bone disease, illness,
or drug use that might affect bone turnover. Bone mineral
density (BMD) at the lumbar spine (L2-4) was measured by
dual energy radiography absorptiometry using a XR-36
(Norland Co., Fort Atkinson, WI, U.S.A.). The precision
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Identification of a Mutation in the Human Raloxifene Response 
Element of the Transforming Growth Factor- 3 Gene
The human transforming growth factor- 3 (TGF- 3) is an important cytokine to
maintain bone mass by inhibiting osteoclast differentiation. Recently raloxifene
response element (RRE), a new enhancer with a polypurine sequence for estro-
gen receptor (ER)-mediated gene activation, was identified on the TGF- 3 gene.
Functional analysis of the RRE-mediated pathway has shown that this would be
an important pathway for bone preserving effect. We found a novel mutation in
the RRE sequence by single-strand conformational polymorphism analysis in
one of 200 Korean women. Cloning and sequencing revealed a heterozygote in
which one allele had an insertion of 20 nucleotides (AGAGAGGGAGAGGGAGA
GGG) between nucleotide +71 and +72 and a point mutation at nucleotide +75
(G-A transition), and the other allele had normal sequence. The insertion was a
nearly perfect tandem duplication of the wild type DNA sequence. The bone min-
eral density of the affected woman was not much lower than that of age-matched
controls. Transient transfection of the mutant allele showed no significantly differ-
ent activity compared with that of the wild type allele. These observations sug-
gest that the heterozygote variation of the RRE sequence seems not to be oper-
ative in determination of bone mass.
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error (coefficient of variation of repeated measurements on
individuals) was 0.7%.
To investigate whether a polymorphic site or mutation
exists on the RRE sequence of the TGF- 3 gene, the region
between nucleotide -258 and+125 relative to the transcrip-
tion start site was amplified by polymerase chain reaction
(PCR) from the genomic DNA prepared from peripheral
white blood cells. The forward primer (5′ -GGGCTCATC
GGAGTAACTTTCC-3′ ) and the reverse primer (5′ -TCTC
TCGGTCATTCCCTTGG-3′ ) were used for PCR. PCR
was carried out by using thermal cycler (Perkin Elmer 9600,
Norwalk, Conn, U.S.A.) with 35 cycles consisting of 30 sec
at 94℃, 30 sec at 58℃, and 30 sec at 72℃. The reaction
mixture was heated at 94℃ for 4 min before the first cycle
and at 72℃ for 7 min after the last cycle. For single-strand
conformation polymorphism analysis (SSCP), a 5.5% non-
denaturing polyacrylamide gel was used and was run in 1×
TBE buffer at 30 watt for 4 hr at 4℃. The PCR product
from the mutant was cloned by TA cloning kit (Invitrogen,
San Diego, CA, U.S.A.) and both alleles were sequenced
using a Sequenase version 2.0 kit (USB, Cleveland, OH,
U.S.A.).
The 41 bp wild type and 61 bp mutant type DNA oligonu-
cleotides were synthesized as the following sequences: wild
type: 5′ -AGAGAGAGGGAGAGGAGCGAGAGGGAG
AGGGAGAGGGAGAG-3′ ; mutant type: 5′ -AGAGAG
AGGGAGAGGAGCGAGAGGGAGAGGGAGAGGG
AGAGAGGGAGAGGGAGAGGGAGAA-3′ .
They cloned into the pGEM-7zf (Promega) encoding
luciferase reporter construct (pGEM-7zf-Luc). For function-
al evaluation of two cloned plasmids such as the wild type
RRE in pGEM-7zf-Luc (pRREw-luc) and the mutant type
RRE in pGEM-7zf-Luc (pRREm-luc), transient transfections
of HELA cells were carried out in 48 well culture plates using
LipofectAMINETM reagent (GIBCO) and the dual-luciferase
reporter assay system (Promega). Cells were cotransfected
with the expression plasmid encoding human ER c-DNA
(pCMVER ) and the reporter plasmids, either pRREw-luc
or pRREm-luc. As a positive control, cells were also cotrans-
fected with pCMVER and pGEM-7zf-Luc encoding mul-
tiple ERE sequences (pEREs-luc).
After 4 hr of transfection, cells were treated with 17 -
estradiol (10
-6 M) or raloxifene (10
-6 M) for 18 hr. Dual
luciferase activity was analyzed in cell lysates according to
the manufacturer’ s instruction. Light intensity was mea-
sured with a Turner luminometer, and firefly luciferase
activity was normalized versus Renilla luciferase activity. 
RESULTS
A polymorphic band was found in one subject. The PCR
product of the subject was cloned into a plasmid vector for
sequencing. One allele had an insertion of 20 nucleotides
(AGAGAGGGAGAGGGAGAGGG) between nucleotide
71 and 72 and a point mutation at nucleotide 75 that replaced
G with A, and the other allele was revealed to have normal
sequence. An insertion was a nearly perfect tandem duplica-
Fig. 1. Single-strand conformation polymorphism (SSCP) analy-
sis on a 5.5% nondenaturing polyacrylamide gel. Different pat-
tern of the bands in lane 6 suggests the existence of genomic
variation.
Fig. 2. DNA sequence of the wild and mutant allele. Direct DNA
sequencing shows a 20 base insertion and a substitution 75 G-
A in the mutant allele.
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tion, which had a 19 base repeat sequence of the wild type
DNA between nucleotide 53 and 71 (Fig. 1, 2). 
A 55-yr-old woman with this mutant RRE was 160 cm
tall. She had one daughter and one son. The morphology of
the breast was normal and the external genitalia and ovaries
were intact. She had had a hysterectomy because of myoma
at the age of 45. The lipid profile was normal. Z score (the
value of the SD obtained when the average of the data was
adjusted to zero) of her spine BMD was -0.93.
The luciferase activity in pEREs-luc transfected cells were
shown to increase significantly after treatment of estrogen or
raloxifene whereas the luciferase activity in both wild and
mutant type RRE did not increase even after treatment of
estrogen or raloxifene. There were no significantly different
activities between the wild type and mutant type RRE either
before or after treatment of estrogen or raloxifene (Fig. 3).
DISCUSSION
We found a heterozygote with a 20 base insertion and one
point mutation of the RRE site in the TGF- 3 gene. Other
polymorphic site could not be found in 200 women.
The functional significance of the mutant RRE remains
unknown. BMD of the subject was comparable to that of
the age-matched controls. These findings suggest that the
RRE mutant of one allele is not likely to be responsible for
the determination of BMD, and the mutant does not seem
to have a dominant effect. However, the possibility can not
be excluded that the homozygote may affect the bone preser-
vation. In case of glucokinase gene, the heterozygote of the
mutant in  -cell specific promoter was more frequently
found in patients with glucose intolerance and showed a
lower transcriptional activity. The homozygote of the variant
was found only in non-insulin-dependent diabetic patients
(7). Further investigation needs to be performed in a large
population to find the homozygote. 
Transient transfection study of this heterozygotic mutant
RRE did not show any significant difference in activity com-
pared with the wild type activity. Furthermore, both wild
and mutant type RRE did not induce the luciferase activity
even after the treatment of raloxifene. These findings suggest
that the wild type RRE as well as the mutant type RRE is
not influenced by raloxifene treatment. This suggestion can
be supported by the report that demonstrated the RRE was
not sufficient to mediate the full hormonal regulation of the
TGF- 3 gene (8).
Our data suggest that the novel RRE mutant seems not
to be a functional mutant and the RRE promoter region may
not be essential to mediate the target gene regulation.
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